Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: A clinical-pathological correlation study

Annals of Oncology

Volumn 17, Issue 4, 2006, Pages 637-645

  Graesslin, O ^a,b,c   Cortez, A ^a,b   Fauvet, R ^b   Lorenzato, M ^d   Birembaut, P ^d,e   Daraï, Emile ^a,b  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Institut Mère   (France)

^d Laboratoire Pol Bouin   (France)

^e INSERM   (France)

Author keywords

Endometrial cancer; Hyperplasia; Immunohistochemistry; Metalloproteinase inhibitors; Metalloproteinases; Normal endometrium

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; MONOCLONAL ANTIBODY; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CANCER GRADING; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CELL; ENDOMETRIUM HYPERPLASIA; EPITHELIUM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MYOMETRIUM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; STROMA CELL;

EID: 33645312651     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj129     Document Type: Article

References (60)

1. Raza SL, Cornelius LA. Matrix metalloproteinases: Pro- and anti-angiogenic activities. J Investigative Dermat Symp Proceed 2000; 5: 47-54.
2. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-2154.
3. Basset P, Bellocq JP, Wolf C. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699-704.
4. Birkedal-Hansen H, Moore WG, Bodden MK et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250.
5. Goldberg GI, Wilhelm SM, Kroneberger A et al. Human fibroblast collagenase. Complete primary structure and homology to an oncogene transformation-induced rat protein. J Biol Chem 1986; 261: 6600-6605.
6. Hasty KA, Jefferey JJ, Hibbs MS. The collagen substrate specificity of neutrophil collagenase. J Biol Chem 1987; 262: 48-52.
7. Van den Steen PE, Opdenakker G, Wormald MR et al. Matrix remodelling enzymes, the protease cascade and glycosylation. Biochimica et Biophysica Acta 2001; 1528: 61-73.
8. Hibbs MS, Hoidal JR, Kang AH. Expression of a metalloproteinase that degrades native type V collagen and denatured collagen by cultured human alveolar macrophages. J Clin Invest 1987; 80: 1644-1650.
9. Wilhelm SM, Collier IE, Marmer BL et al. SV40-transformed human lung fibroblasts secrete a 92kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989; 264: 17213-17221.
10. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15: 61-75.
11. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 2062-2072.
12. Rodgers W. Matrix metalloproteinases and carcinogenesis. Hum Pathol 1999; 30: 363-364.
13. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-1270.
14. Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335: 640-649.
15. Prat J. Prognostic parameters of endometrial carcinoma. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004; 35: 649-662.
16. Mutter GL and The Endometrial Study Group. Endometrial intraepithelial neoplasia (EIN): Will it bring order to chaos. Gynecol Oncol 2000; 76: 287-290.
17. Sherman ME. Theories of endometrial carcinogenesis: A multidisciplinary approach. Mod Pathol 2000; 13: 295-308.
18. Inoue M. Current molecular aspects of the carcinogenesis of the uterine endometrium. Int J Gynecol Cancer 2001; 11: 339-348.
19. Jovanovic AS, Boynton KA, Mutter GL. Uteri of women with endometrial carcinoma contain a histopathologic spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Research 1996; 56: 1917-1921.
20. Mutter GL, Boynton KA, Faquin WC et al. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Research 1996; 56: 4483-4486.
21. Leblanc M, Poncelet C, Soriano D et al. Alteration of CD44 and cadherins expression: Possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. Virchows Arch 2001; 438: 78-85.
22. Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998; 29: 1150-1159.
23. Niemann TH, Trgovac TL, McGaughy VR, Vaccarell L. Bcl-2 expression in endometrial hyperplasia and carcinoma. Gynecol Oncol 1996; 63: 318-322.
24. Vassileva V, Millar A, Briollais L et al. Apoptotic and growth regulatory genes as mutational targets in mismatch repair deficient endometrioid carcinomas of young patients. Oncol Reprod 2004; 11: 931-937.
25. Bulletti C, Jasonni VM, Polli V et al. Basement membrane in human endometrium: Possible role of proteolytic enzymes in developing hyperplasia and carcinoma. Ann NY Acad Sci 1991; 622: 376-382.
26. Goffin F, Munaut C, Frankenne F et al. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium. Biol Reprod 2003; 69: 976-984.
27. Kokorine I, Marbaix E, Henriet P et al. Focal cellular origin and regulation of interstitial collagenase (matrix metalloproteinase-1) are related to menstrual breakdown in the human endometrium. J Cell Sci 1996; 109 (Pt 8): 2151-2160.
28. Soini Y, Alarakkola E, Auto-Harmainen H. Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Hum Pathol 1997; 28: 220-226.
29. Määtä M, Soini Y, Liakka A, Auto-Harmainen H. Localization of MT1-MMP, TIMP-1, TIMP-2 and TIMP-3 messenger RNA in normal, hyperplastic and neoplastic endometrium. Enhanced expression by endometrial carcinomas is associated with low differentiation. Am J Clin Pathol 2000; 114: 402-411.
30. Aglund A, Rauvala M, Puistola U et al. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer - MMP-9 correlates to the grade and the stage. Gynecol Oncol 2004; 94: 699-704.
31. Di Nezza LA, Misajon A, Zhang J et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 2002; 94: 1466-1475.
32. Guo W, Chen G, Zhu C, Wang H. Expression of matrix metalloproteinase-2, -9 and it's tissue inhibitor-1, -2 in endometrial carcinoma. Zhonghua Fu Chan Ke Za Zhi 2002; 37: 604-607.
33. Uzan C, Cortez A, Dufournet C et al. Eutopic endometrium and peritoneal, ovarian and bowel endometriotic tissues express a different profile of matrix metalloproteinases -2, -3, and -11, and of tissue inhibitor metalloproteinases -1 and -2. Virchows Arch 2004; 445; 603-609.
34. Moser PL, Hefler L, Tempfer C et al. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer. Anticancer Res 1999; 19: 2365-2368.
35. Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1 and TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000; 17: 673-681.
36. Benedet JL, Bender H, Jones H 3rd et al. FIGO staging classifications and clinical practice guidelines in the management of gynaecologic cancers. FIGO committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70: 209-262.
37. Tamakoshi K, Kikkawa F, Nawa A et al. Characterization of extracellular matrix degrading proteinase and its inhibitor in gynaecologic cancer tissues with clinically different metastatic form. Cancer 1995; 76: 2565-2571.
38. Park DW, Ryu HS, Choi DS et al. Localization of matrix metalloproteinases on endometrial cancer cell invasion in vitro. Gynecol Oncol 2001; 82: 442-449.
39. Ueno H, Yamashita K, Azumano I et al. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer 1999; 84: 470-477.
40. Wang FQ, So J, Reierstad S, Fishman DA. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 2005; 114: 19-31.
41. Inoue Y, Abe K, Obata K et al. Immunohistochemial studies on matrix metalloproteinase-9 (MMP-9) and type IV collagen in endometrial carcinoma. J Obstet Gynaecol Res 1997; 23: 139-145.
42. Iurlaro M, Loverro G, Vacca A et al. Angiogenesis extent and expression of matrix metalloproteinase -2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest 1999; 29: 793-801.
43. Leong AS-Y. Quantitation in Immunohistology: Fact or fiction? Appl Immunohistochem Mol Morphol 2004; 12: 1-7.
44. Wiegand S, Dünne AA, Müller HH et al. Metaanalysis of the significance of Matrix Metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma. Cancer 2005; 104: 94-100.
45. Ferguson SE, Olshen AB, Viale A et al. Gene expression profiling of tamoxifen-associated uterine cancers: Evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol 2004; 92: 719-725.
46. Laird SM, Dalton CF, Okon MA et al. Metalloproteinases and tissue inhibitor of metalloproteinase 1 (TIMP-1) in endometrial flushings from pre- and post-menopausal women and from women with endometrial carcinoma. J Reprod Fertil 1999; 115: 225-232.
47. Giannelli G, Bergamini C, Marinosci F et al. Clinical role of MMP-2/ TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002; 97: 425-431.
48. Xiao M, Zhou NX, Huang ZQ et al. The ratio of MMP-2 to TIMP-2 in hilar cholangiocarcinoma: A semi-quantitative study. Hepatobiliary Pancreat Dis Int 2004; 3: 599-602.
49. Fan YZ, Zhang JT, Yang HC, Yang YQ. Expression of MMP-2, TIMP-2 protein and the ratio of MMP-2/TIMP-2 in gallbladder carcinoma and their significance. World J Gastroenterol 2002; 8: 1138-1143.
50. Curran S, Dundas SR, Buxton J et al. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004; 10: 8229-8234.
51. Nakopoulou L, Katsarou S, Giannopoulou I et al. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients survival in breast cancer. Mod Pathol 2002; 15: 26-34.
52. Polette M, Nawrocki-Raby B, Gilles C et al. Tumour invasion and matrix metalloproteinases. Critical Rev Oncol Hematol 2004; 49: 179-186.
53. Goffin F, Frankenne F, Beliard A et al. Human endometrial epithelial cells modulate the activation of gelatinase a by stromal cells. Gynecol Obstet Invest 2002; 53: 105-111.
54. Li GY, Fridman R, Kim HRC. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999; 59: 6267-6275.
55. Zhang J, Hamton AL, Nie G, Salamonsen LA. Progesterone inhibits activation of latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP: Enzymes co-ordinately expressed in human endometrium. Biol Reprod 2000; 62: 85-94.
56. Salamonsen LA, Zhang J, Hampton A, Lathbury L. Regulation of matrix metalloproteinases in human endometrium. Hum Reprod 2000; 15 (Suppl 3): 112-119.
57. Wilson CL, Matrisian LM. An epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem 1996; 28: 123-136.
58. Bruner-Tran KL, Eisenberg E, Yeaman GR et al. Steroïd and cytokine regulation of metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice. J Clin Endocrinol Metab 2002; 87: 4782-4811.
59. Li W, Savinov AY, Rozanov DV et al. Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets α1-Antitrypsin Serpin. Cancer Res 2004; 64: 8657-8865.
60. Zhao YG, Xiao AZ, Newcomer RG et al. Activation of progelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem 2003; 17: 15056-15064.